机译:多学科治疗对淋巴结阳性直肠癌的影响
MATTHEW ROOS, M.D.,* JAN H. WONG, M.D.,*[double dagger] SHARMILA ROY-CHOWDHURY, M.D.,* SHARON S. LUM, M.D.,*JOHN W. MORGAN, DR.P.H.,[dagger][double dagger] KEVORK KAZANJIAN, M.D.*From the *Division of Surgical Oncology and [dagger] School of Public Health, Loma Linda University Schoolof Medicine, Loma Linda, California and Region 5 of the California Cancer Registry, Desert SierraCancer Surveillance Program, Loma Linda University Medical Center, Loma Linda, CaliforniaSupported in part by NCI SEER contracts N02-PC-15105 and CDC NPCR contract U58DP000807-01.Presented at the 21st Annual Scientific Meeting of the Southern California Chapter of the American College of Surgeons in Santa Barbara, CA, January 22-24, 2010.Address correspondence and reprint requests to Kevork Kazanjian, M.D., Loma Linda University School of Medicine, Department of Surgery, Division of Surgical Oncology, 1 1 175 Campus Street, CP 21 1 1 1, Loma Linda, CA 92350. E-mail: kkazanjian@llu.edu.;
机译:多学科治疗对淋巴结阳性直肠癌的影响
机译:淋巴结阳性直肠癌术前与术后化疗及放疗后的死亡率风险
机译:高剂量近距离放射疗法结合超分割外照射对局部前列腺癌的治疗后直肠出血:高剂量近距离放射疗法中直肠剂量对2级或更严重直肠出血的影响。
机译:Neoadjuvant在直肠癌中治疗:我们总是需要放射治疗 - 或者我们是否可以更好地评估当地先进的直肠癌?
机译:直肠癌放化疗前后程序性细胞死亡配体1表达和CD8阳性T细胞浸润的模式
机译:21个基因的复发评分分析影响了ER阳性淋巴结阴性和淋巴结阳性的早期乳腺癌的辅助治疗建议从而导致化疗的风险适应性改变
机译:切除的pT1-2淋巴结阳性的直肠癌是否需要辅助放疗?